Study: Safety and Efficacy of the Xanomeline Transdermal Therapeutic System (TTS) in Patients with Mild to Moderate Alzheimers Disease.
Phase II
· Site: 705 (USA) (Dr. Muller)
· consented 2014-01-08
Adverse events
1
Serious AEs
0
Open data queries
0
Luna dropout signal
–
Adverse events
moderate
assessed
2026-08-18
Moderate HYPERBILIRUBINAEMIA — outcome: NOT RECOVERED/NOT RESOLVED; onset 2014-01-26 (study day 19.0); relationship: REMOTE
Data queries
No data queries.
☾ Luna engagement
This participant doesn't use Luna.